Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 2260Lung Neoplasms 1048Small Cell Lung Carcinoma 402Adenocarcinoma of Lung 154Mesothelioma, Malignant 120Breast Neoplasms 110Neoplasms 106Brain Neoplasms 101Neoplasm Metastasis 95Melanoma 72Mesothelioma 70NSCLC 68Colorectal Neoplasms 68Adenocarcinoma, Bronchiolo-Alveolar 56Thymoma 53Pancreatic Neoplasms 52Ovarian Neoplasms 46Head and Neck Neoplasms 46Carcinoma, Renal Cell 43Carcinoma 38Stomach Neoplasms 36Sarcoma 35Prostatic Neoplasms 35Esophageal Neoplasms 34Adenocarcinoma 34Uterine Cervical Neoplasms 33Squamous Cell Carcinoma of Head and Neck 33Pleural Effusion, Malignant 33Recurrence 27Urinary Bladder Neoplasms 26

Interventions

Erlotinib Hydrochloride 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasm Recurrence, Local × Thoracic × Clear all
NCT00095225 2008-01-29

A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)

Genentech, Inc.

Phase 2 Completed
122 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Recurrence, Local, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡